BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-69@catalystbrief.girapphe.com
DTSTAMP:20261117T061554Z
LAST-MODIFIED:20261117T061554Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Almirall\, S.A. — Lebrikizumab [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Lebrikizumab Treatment i
 n Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis.\nSourc
 e: https://clinicaltrials.gov/study/NCT06526182\nhttps://catalystbrief.gir
 apphe.com/e/69?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/69?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
